SYNDAX PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

SNDX

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

On October 4, 2021, Daphne Karydas notified Syndax Pharmaceuticals, Inc. (the "Company") of her intention to resign as chief financial officer, treasurer, principal financial officer and principal accounting officer of the Company, effective October 22, 2021, in order to pursue another opportunity. Ms. Karydas will remain with the Company to assist with the transition through the end of the year. Ms. Karydas' resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Company has appointed Alexander Nolte, the Company's Vice President, Chief Accounting Officer, as its principal accounting officer and interim principal financial officer effective upon Ms. Karydas' departure. Mr. Nolte will serve as the Company's principal accounting officer and interim principal financial officer as the Company conducts a search for a new chief financial officer.

Mr. Nolte, age 49, has served as the Company's Vice President, Chief Accounting Officer since September 2021 and previously served as Vice President, Corporate Finance since February 2021 and as Corporate Controller since April 2017. Prior to that, Mr. Nolte served as Corporate Controller from July 2015 to April 2017 at CoLucid Pharmaceuticals, responsible for the financial operations of the company. From September 2013 to July 2015, Mr. Nolte served as Director of Revenue Recognition and International Accounting at Aegerion Pharmaceuticals. From March 2008 to September 2013, Mr. Nolte held several finance positions at Genzyme Corporation.

Item 9.01. Financial Statements and Exhibits.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses